Drugs / cytotoxic T lymphocyte
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05262673 | Jun 2026 → Dec 2029 expected | B-cell acute lymphoblastic leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytotoxic T lymphocyte | “cytotoxic T lymphocyte (CTL)-based immunotherapy” NCT05262673 ↗ |
| Known as | CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05262673 ↗ |
| Modality | Cell therapy | “engineered immune effector CTLs” NCT05262673 ↗ |